Shares of Derma Sciences Inc. (NASDAQ:DSCI) fell 2.1% during mid-day trading on Friday . The company traded as low as $4.67 and last traded at $4.74, with a volume of 112,946 shares. The stock had previously closed at $4.84.

A number of brokerages recently issued reports on DSCI. Zacks Investment Research raised Derma Sciences from a “hold” rating to a “buy” rating and set a $5.75 price objective for the company in a research report on Wednesday, August 3rd. TheStreet raised Derma Sciences from a “sell” rating to a “hold” rating in a research report on Tuesday, August 9th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $7.35.

The company’s 50-day moving average price is $4.82 and its 200 day moving average price is $3.91. The stock’s market capitalization is $133.60 million.

Derma Sciences (NASDAQ:DSCI) last posted its earnings results on Tuesday, August 9th. The company reported $0.08 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.08) by $0.16. The firm had revenue of $22.20 million for the quarter, compared to analysts’ expectations of $22.40 million. On average, equities analysts anticipate that Derma Sciences Inc. will post ($0.04) earnings per share for the current fiscal year.

Derma Sciences, Inc (Derma Sciences) is a medical device company. The Company operates through two segments: advanced wound care and traditional wound care products. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.